Background: Red cell transfusions remain a mainstay of therapy for patients with sickle cell
disease (SCD), but pose significant clinical challenges. Guidance for specific indications and …

Endogenous rhythmicity likely evolved as a mechanism allowing organisms to anticipate
predictable daily changes in the environment (Rutter et al., 2002). Under homeostasis, murine …

The potential of allogeneic UCB for HCT and novel cell-based therapies is undervalued and
underutilized. The inventory of high-quality UCB units available from public cord blood …

Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by painful vaso-occlusive
crises (VOC) and chronic hemolysis. The mononuclear phagocyte system is pivotal …

Previous studies using intravital microscopy in a sickle cell disease (SCD) mouse model
suggest that adherent white blood cells (WBCs) play a key role in vaso-occlusion by capturing …

Gene therapy for sickle cell disease is limited by the yield of hematopoietic progenitor cells
that can be harvested for transduction or gene editing. We therefore performed a phase I dose…

Patients with sickle cell disease (SCD) suffer from intravascular hemolysis-associated vascular
injury and tissue damage. Classical monocytes (CMo), which are the most abundant of …

Transfusion therapy is a life‐sustaining treatment for patients with sickle cell disease (SCD),
but can cause serious complications including alloimmunization. We previously reported …

Ebola virus (EBOV) hemorrhagic fever outbreaks have been challenging to deter due to the
lack of health care infrastructure in disease-endemic countries and a corresponding inability …

Sickle cell disease (SCD) is characterized by hemolytic anemia, which can trigger oxidative
stress, inflammation, and tissue injury that contribute to disease complications. Bone marrow …